Partner Press Releases

Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment MedCity News, October 13, 2009
A Cleveland startup company developing stem cell therapies has struck a deal with medical technology giant Medtronic Inc. that could propel the business.

America's Most Promising Companies 2009 Forbes.com, September 16, 2009
Ten Questions For Quality Electrodynamics

Akebia Announces Initiation of Phase 1 Clinical Study of AKB-6548 Akebia Press Release, September 15, 2009
First-in-man study started for compound designed to increase natural production of erythropoietin

Arpida and Evolva Plan Merger Arpida Press Release, September 10, 2009
Proposed merger creates new company focused on development of drugs that address high unmet medical needs

Cleveland quietly becoming leader in adult stem cell industry Plain Dealer, August 17, 2009
George Reed, 73, still remembers the day his cardiologist told him there was nothing more he could do. Coronary bypass surgeries, stent procedures, defibrillators and pacemakers — he’d been through it all. A “no-option patient,” the doctors called him. Another invasive procedure was out of the question. His heart, weakened by diffuse coronary artery disease, wouldn’t be able to take it, his doctors said. The Ashtabula policeman had one last hope: stem cell therapy.

Akebia Completes $16M expansion of Series A Financing Akebia Press Release, July 28, 2009
Increases Total Series A Round to $25M

Evolva successfully completes Phase I Single Ascending Dose Trial on EV-077 for renal and cardiovascular indications Evolva Press Release, July 16, 2009
Evolva SA, a Swiss headquartered international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has completed a single ascending dose Phase I clinical trial in healthy volunteers with EV-077-3201-2TBS.

Arteriocyte Medical Systems’ work shows promise toward developing artificial blood Plain Dealer, June 30, 2009
Lab results at a small biotechnology firm in Cleveland show early promise for creating a machine that can produce large quantities of pre-packaged artificial blood. But researchers expect the technology will not be ready for use for at least a couple of years.

Sensible Medical Innovation Gets $7 Million to Develop Noninvasive Device to Detect Congestive Heart Failure Venture Capital News, June 24, 2009
Sensible Medical Innovation announced today that it has received a $7 million in capital to develop a noninvasive device to detect congestive heart failure. The funding for this innovation came from two vc firms, Vitalife and Genisis Partners.

Mentor medical device maker's partnerships open new opportunities Crain's Cleveland Business, June 22, 2009
Outside inventors' ideas materialize through Frantz

Akebia Adds $15M in Series A for Anemia, Vascular Disease Drugs BioWorld Today, December 19, 2008
Akebia Therapeutics Inc. raised $15.1 million in Series A funds to push products into clinical testing next year.

Proxy Biomedical Ltd. of Ireland ready to set up shop in Cleveland The Plain Dealer, December 06, 2008
A company specializing in materials for tissue repair could be first in a pipeline of Irish businesses looking to ply the region's biomedical cluster.

Athersys' stem-cell therapy used at Clinic in 1st clinical trial patient The Plain Dealer, October 15, 2008
The adult stem-cell therapy developed by Athersys Inc., a Cleveland biopharmaceutical company, has been used successfully to treat its first clinical trial patient at the Cleveland Clinic.

AcelleRX Therapeutics, a Cleveland Clinic spinoff, raises $6.9 million for heart drug SDF-1 The Plain Dealer, October 10, 2008
A Cleveland Clinic spinoff that is developing a biologic therapy to repair damaged hearts has attracted $6.9 million in its first fund-raising round.

Biomedical startup with $600,000 promise from investors moving to NE Ohio The Plain Dealer, July 24, 2008
A biomedical startup company that developed a mechanical system to clear drainage catheters has been promised $600,000, mostly from Northeast Ohio investors.

Medtronic Inc., Arteriocyte Medical Systems of Cleveland strike deal The Plain Dealer, November 07, 2007
A Cleveland startup company developing stem cell therapies has struck a deal with medical technology giant Medtronic Inc. that could propel the business.